| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
pro November 2026 Larimar Therapeutics Corporate Deck Exhibit 99.2 |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update |
| 29 Jun 2026 |
8-K: Other Events
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia |
| 19 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 19, 2026, Larimar Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually. As of March 25, 2026, the record date for the Annual Meeting, there were 103,882,937 outstanding s... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results |
| 09 Mar 2026 |
8-K: Other Events
Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this pres... |
| 27 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
Introductory. Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggr... |
| 24 Feb 2026 |
8-K: Other Events
Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this pres... |
| 22 Jan 2026 |
8-K: Unregistered Sales of Equity Securities; Amendments to Articles/Bylaws; Change in Fiscal Year
This letter agreement (the “Agreement”) confirms the agreement of Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), and the holder of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) lis... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this pres... |
| 17 Dec 2025 |
8-K: Unregistered Sales of Equity Securities; Amendments to Articles/Bylaws; Change in Fiscal Year
This letter agreement (the “Agreement”) confirms the agreement of Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), and the holder of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) lis... |
| 10 Nov 2025 |
8-K: Other Events
Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this pres... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Larimar Therapeutics Reports Third Quarter 2025 Financial Results |
| 14 Oct 2025 |
8-K: Other Events
Forward-Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ( “Company”) and on information currently available to management. All statement... |
| 29 Sep 2025 |
8-K: Other Events
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 |
| 31 Jul 2025 |
8-K: Entry into a Material Definitive Agreement
Introductory. Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggr... |
Loading...